Search - tctmd.com

Displaying 241 - 260 of 557

Sort: Relevancy | Date

Minority Women Face 50% Increased Risk of Death/MI After PCI Compared With White Men at 1 Year

News Conference News SCAI 2017

Minority Women Face 50% Increased Risk of Death/MI After PCI Compared With White Men at 1 Year

May 18, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

News Daily News

Abbott Vascular Recalls Three Coronary Catheters Because of Possible Sheath Removal Problems

May 16, 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding

News Conference News EuroPCR 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Yael L. Maxwell

May 16, 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

Bioresorbable Scaffolds: Where Do We Go From Here?

News Conference News SCAI 2017

Bioresorbable Scaffolds: Where Do We Go From Here?

May 15, 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

May 12, 2017

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

May 05, 2017

Absorb BVS Recalled in Australia From All Centers Not Studying Device

News Daily News

Absorb BVS Recalled in Australia From All Centers Not Studying Device

May 03, 2017

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

News Daily News

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

May 03, 2017

Non-O Blood Types May Impart Higher Cardiovascular Risk

News Daily News

Non-O Blood Types May Impart Higher Cardiovascular Risk

May 02, 2017

TCTMD’s Top 10 Most Popular Stories for April 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2017

April 28, 2017

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

News Daily News

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

April 27, 2017

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

The Left Main Debate: What Does it Mean for the Future of Intervention?

News Opinion Fellow Talk

The Left Main Debate: What Does it Mean for the Future of Intervention?

Tiffany Patterson, MBBS

April 12, 2017

Absorb BVS Use Restricted in Europe

News Daily News

Absorb BVS Use Restricted in Europe

Michael O'Riordan

April 06, 2017

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.